Free tool
FAERS Monitor: Hycamtin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020981 or its brand name (Hycamtin, Topotecan Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
6,942
Serious
6,366
92% of reports
Hospitalization
2,628
Death reported
1,654
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia603
- anaemia580
- off label use575
- death573
- neutropenia559
- nausea477
- disease progression457
- thrombocytopenia453
- pyrexia449
- vomiting437
- product use in unapproved indication377
- fatigue337
- white blood cell count decreased326
- diarrhoea324
- malignant neoplasm progression321
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 138 |
| 2005 | 216 |
| 2006 | 123 |
| 2007 | 185 |
| 2008 | 159 |
| 2009 | 201 |
| 2010 | 238 |
| 2011 | 259 |
| 2012 | 313 |
| 2013 | 231 |
| 2014 | 301 |
| 2015 | 394 |
| 2016 | 397 |
| 2017 | 347 |
| 2018 | 408 |
| 2019 | 340 |
| 2020 | 473 |
| 2021 | 490 |
| 2022 | 430 |
| 2023 | 355 |
| 2024 | 344 |
| 2025 | 396 |
| 2026 | 203 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,217 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 603 | 27.8 | 25.7 | 15,451 |
| neutropeniaSignal | 559 | 12.5 | 11.5 | 5,919 |
| thrombocytopeniaSignal | 453 | 12.3 | 11.3 | 4,706 |
| disease progressionSignal | 457 | 11.7 | 10.7 | 4,489 |
| malignant neoplasm progressionSignal | 321 | 9.5 | 8.6 | 2,445 |
| anaemiaSignal | 580 | 9.2 | 8.5 | 4,279 |
| white blood cell count decreasedSignal | 326 | 9.1 | 8.2 | 2,359 |
| product use in unapproved indicationSignal | 377 | 4.6 | 4.2 | 1,075 |
| pyrexiaSignal | 449 | 3.9 | 3.6 | 995 |
| vomitingSignal | 437 | 2.8 | 2.6 | 522 |
| deathSignal | 573 | 2.0 | 1.9 | 305 |
| off label use | 575 | 2.0 | 1.8 | 294 |
| nausea | 477 | 1.8 | 1.7 | 184 |
| diarrhoea | 324 | 1.5 | 1.4 | 59 |
| fatigue | 337 | 1.3 | 1.2 | 26 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.